TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Liminatus Pharma ( (LIMN) ) has provided an announcement.
On August 14, 2025, Liminatus Pharma announced an update on its CD47 checkpoint inhibitor, IBA101, which is designed to synergize with PD-1/PD-L1 inhibitors. As patents for existing PD-1/PD-L1 therapies are set to expire, IBA101 offers a strategic opportunity to extend the life cycle of these therapies through new combination indications. The company highlights IBA101’s unique ability to activate innate immune responses without the cytopenia issues seen in earlier CD47 programs, positioning it as a valuable asset in the competitive immuno-oncology landscape.
More about Liminatus Pharma
Liminatus Pharma, Inc. operates in the immuno-oncology industry, focusing on developing innovative therapies such as CD47 checkpoint inhibitors. The company is positioned to address the challenges faced by the PD-1/PD-L1 inhibitor market, which is nearing a patent cliff, by offering novel combination therapies.
Average Trading Volume: 599,393
Technical Sentiment Signal: Sell
Current Market Cap: $117.7M
For a thorough assessment of LIMN stock, go to TipRanks’ Stock Analysis page.